AngioDynamics (NASDAQ:) has recently reported its fiscal first-quarter 2025 results, with net sales falling short of projections. Despite this, H.C. Wainwright has maintained its Buy rating and $14.00 stock price target for the company.
In the detailed financial results, AngioDynamics disclosed net sales of $67.5 million for the quarter ending August 31, below analysts' expectations. However, on a pro forma basis, net sales showed a modest increase of 1.1% year-over-year.
The Med Tech segment saw a rise in net sales, while the Med Device segment experienced a decrease. The company reported a net loss of $12.8 million, higher than anticipated.
Despite the mixed performance, AngioDynamics has reiterated its full-year 2025 guidance, expecting growth in both segments and projecting a gross margin of 52-53%.
InvestingPro Insights
Recent data shows that AngioDynamics has a market capitalization of $247.87 million and maintains a strong liquidity position. However, the company is not profitable over the last twelve months, with a negative P/E ratio.
Investors should consider the company's financial stability and market reaction following the recent earnings report. InvestingPro offers additional tips for a comprehensive analysis of AngioDynamics.
This article provides an in-depth analysis of AngioDynamics' financial performance and market outlook, offering insights for investors to make informed decisions.